Impact of the US Food and Drug Administration warning regarding increased risk of aortic aneurysms or aortic dissections on fluoroquinolone prescribing trends.

John George RizkJulia F SlejkoEmily L HeilDominique SeoDanya M Qato

Published in: BMJ open quality (2024)

We did not find a change in FQ prescription rates after the warning. The utility of safety advisories as a primary tool for mitigating FQ use in high-risk populations should be revisited.

Keyphrases

drug administration
aortic valve
pulmonary artery
left ventricular
primary care
aortic dissection
emergency department
coronary artery
heart failure
human health
pulmonary arterial hypertension
pulmonary hypertension
adverse drug
electronic health record